Amanda Hernandez-Jones, MD
Neurology · Farmington, CTNPI 1861849473
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Genentech USA, Inc. at 39.6% of the total. 2025 is the largest year on record at $230,945, more than ten times the $193 reported in 2021. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $758.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$120K
- AstraZeneca$68K
- Argenx US, Inc.$40K
- Amgen$20K
- F. Hoffmann-la Roche AG$17K
- Merck Kgaa$12K
- plus $26K from 14 others
Across 1 payment — averaging $3484.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3K
What the payments were for
- Consulting fees$92,88431%
- Speaking & faculty fees$152,44850%
- Travel & lodging$47,14616%
- Food & beverage$10,9354%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 152 | $120,111 |
| AstraZeneca | 88 | $67,606 |
| Argenx US, Inc. | 46 | $40,074 |
| Amgen | 21 | $19,945 |
| F. Hoffmann-la Roche AG | 4 | $17,375 |
| Merck Kgaa | 5 | $12,089 |
| UCB, Inc. | 11 | $10,153 |
| Genentech, Inc. | 14 | $4,771 |
| EMD Serono, Inc. | 17 | $3,778 |
| TG Therapeutics, Inc. | 9 | $3,697 |
| Merck Healthcare Kgaa | 3 | $1,565 |
| Janssen Scientific Affairs, LLC | 3 | $1,237 |
| Johnson & Johnson | 5 | $354 |
| Biogen | 4 | $204 |
| AbbVie(2 entities) | 12 | $197 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Amylyx Pharmaceuticals, Inc. | 1 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $51 |
| Medtronic | 2 | $40 |
| CSL Behring | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$110,075
- ULTOMIRIS$64,692
- Ocrevus Zunovo$44,919
- VYVGART$34,452
- UPLIZNA$8,192
- Enspryng$4,127
- BRIUMVI$3,467
- Rystiggo$2,940
- VYVGART HYTRULO$2,000
- Zilbrysq$1,140
- NURTEC ODT$125
How this compares
$303,446 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 20 | $894,511 |
| FirdapseAmifampridine Phosphate | 13 | $418,614 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $411,062 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 28 | $369,846 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 48 | $361,586 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 36 | $110,165 |
| Pyridostigmine Bromide | 62 | $9,885 |
| Mycophenolate Mofetil | 45 | $6,075 |
| Azathioprine | 18 | $1,457 |
| Gabapentin | 37 | $906 |
| Prednisone | 72 | $777 |
| Pregabalin | 12 | $378 |
| Duloxetine Hcl | 18 | $302 |
| RizatriptanRizatriptan Benzoate | 11 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris | $67,606 | $894,51120 claims |
| CSL BehringPrivigen | $21 | $369,84628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.
Other neurology in Farmington
- Wanda Castro-BorreroFarmington$553K
- Ashmanie MahatooFarmington$92K
- Jaime Imitola HerreraFarmington$53K
- Hamza CobanFarmington$17K
- Matthew ImperioliFarmington$13K
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Derek SmithNorwich$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.